StreetInsider.com News Articles

Agenus drug combo shows 33% three-year survival in colorectal cancer

Fri, 28 Aug 2026 10:07:39 -0400

Agenus Inc. (Nasdaq: AGEN) announced the peer-reviewed publication of mature Phase 1b clinical results evaluating the combination of botensilimab (BOT) and balstilimab (BAL) in patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases.

The study, published in Clinical Cancer Research, analyzed 123 heavily pretreated patients who had received a median of three prior lines of therapy. The combination demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33%. Available later-line standard treatments have reported median overall survival of approximately 10 to 14 months in comparable patient populations.

The confirmed objective response rate was

Agenus drug combo shows 33% three-year survival in colorectal cancer

Fri, 28 Aug 2026 10:07:39 -0400

The confirmed objective response rate was

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism

Fri, 28 Aug 2026 10:07:00 -0400

Mature 123 patient analysis reports 21.2-month median overall survival and 33% three-year overall survival in heavily pretreated MSS mCRC without active liver metastases
Responses observed in tumors with low tumor mutational burden and no PD-L1 expression, reinforcing BOT’s Fc-enhanced immune priming mechanism in immunologically “cold” tumors
Durable clinical activity and biomarker findings add biological rationale for evaluating BOT+BAL earlier in the disease course, including curative-intent neoadjuvant colon cancer

Agenus reports no recurrences in Phase 2 colon cancer drug trial

Wed, 26 Aug 2026 10:05:23 -0400

Agenus Inc. (Nasdaq: AGEN) published updated results from its Phase 2 NEST trial evaluating a combination of botensilimab (BOT) and balstilimab (BAL) as a pre-surgical treatment in patients with resectable colon cancer, according to a press release.

The manuscript was published in Clinical Cancer Research. As of the March 31, 2026 data cutoff, no colorectal cancer recurrences had been observed, with a median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2.

Among 22 mismatch repair proficient/microsatellite stable (pMMR/MSS) tumors, the drug combination achieved a 59% pathologic response rate, including a 41% major pathologic response rate and a 32% pathologic

Agenus reports no recurrences in Phase 2 colon cancer drug trial

Wed, 26 Aug 2026 10:05:23 -0400

Agenus reports no recurrences in Phase 2 colon cancer drug trial

Wed, 26 Aug 2026 10:05:23 -0400

Agenus reports no recurrences in Phase 2 colon cancer drug trial

Wed, 26 Aug 2026 10:05:23 -0400

Agenus reports no recurrences in Phase 2 colon cancer drug trial

Wed, 26 Aug 2026 10:05:23 -0400

Agenus reports no recurrences in Phase 2 colon cancer drug trial

Wed, 26 Aug 2026 10:05:23 -0400

Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Wed, 26 Aug 2026 10:05:00 -0400

No colorectal cancer recurrences observed at updated median follow-up of 32.2 months in NEST-1 and 23.5 months in NEST-2
In pMMR/MSS tumors, neoadjuvant BOT+BAL achieved 59% pathologic response, including 41% major pathologic response and 32% pathologic complete response
88% of evaluable patients cleared ctDNA before surgery, with no delays to planned surgical resection
Longer follow-up and immune analysis provide clinical and biological support for Agenus’ planned global Phase 3 ROBBIN trial in curative-intent MSS/pMMR colon cancer